Ultrasound and fetal diagnosis

Current Opinion in Obstetrics and Gynecology

Volumn 17, Issue 2, 2005, Pages 185-195

  Filkins, Karen ^a,c   Koos, Brian J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

Aneuploidy; Doppler; Fetus; Genetic screening; Growth; Pregnancy

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

BRAIN VENTRICLE DILATATION; CROWN RUMP LENGTH; DOPPLER FLOWMETRY; DOWN SYNDROME; FACIAL BONE; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GENETIC SCREENING; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SECOND TRIMESTER PREGNANCY; THREE DIMENSIONAL IMAGING; TRISOMY 18; TRISOMY 21;

EID: 15944424314     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gco.0000162190.83972.5a     Document Type: Review

References (105)

1. Cicero S, Rembouskos G, Vandecruys H, et al. Likelihood ratio for trisomy 21 in fetuses with absent nasal bone at 11-14 week scan. Ultrasound Obstet Gynecol 2004; 23:218-223. Rates for absent nasal bone are defined for Caucasians, Afro-Caribbeans, and Asians.
2. Cicero S, Bindra R, Rembouskos G, et al. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free β-hCG and PAPP-A at 11-14 week. Prenat Diagn 2003; 23:306-310. This describes the basis for a first-trimester integrated approach to maximize detection and minimize the screen positive rates.
3. Vintzileos A, Walters C, Yeo L. Absent nasal bone in the prenatal detection of fetuses with trisomy 21 in a high-risk population. Obstet Gynecol 2003; 101:905-908.
4. Viora E, Marturzo B, Errante G, et al. Ultrasound evaluation of fetal nasal bone at 11-14 weeks in a consecutive series of 1906 fetuses. Prenat Diagn 2003; 23:784-787.
5. Kelekci S, Yazicioglu HF, Oguz S, et al. Nasal bone measurement during the first trimester: is it useful? Gynecol Obstet Invest 2004; 58:91-95. Measurements were successful in 93%, with absent or small nasal bone more common in abnormal fetuses.
6. Minderer S, Gloning KP, Henrich W, Stoger H. The nasal bone in fetuses with trisomy 21: sonographic versus pathomorphological findings. Ultrasound Obstet Gynecol 2003; 22:16-21.
7. Malone F, Ball RH, Nyberg DA, et al. First-trimester nasal bone evaluation for aneuploidy in the general population. Obstet Gynecol 2004; 104:1222-1228. The usefulness of nasal bone screening in a low-risk population needs further evaluation.
8. Spencer K, Bindra R, Nix ABJ, et al. Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol 2003; 22:142-148.
9. Borrell A, Casals E, Fortuny A, et al. First-trimester screening for trisomy 21 combining biochemistry and ultrasound at individually optimal gestational ages: an interventional study. Prenat Diagn 2004; 24:541-545. PAPP-A and free β-hCG at 7-12 weeks of gestation with nuchal translucency at 10-14 weeks detected 88% of Down syndrome and 75% of trisomy 18 with a 3.3% screen-positive rate.
10. Spencer K, Spencer CE, Power M, et al. Screening of chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 2003; 110:281-286.
11. Müller MA, Pajkrt E, Bleker OP, et al. Disappearance of enlarged nuchal translucency before 14 weeks' gestation: relationship with chromosomal abnormalities and pregnancy outcome. Ultrasound Obstet Gynecol 2004; 24:169-174. Disappearance of enlarged nuchal translucency was still associated with an 8% risk of aneuploidy, although the risk was higher (35%) in the persistent group.
12. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J of Obstet Gynecol 2004; 191:45-67. The importance of complete anatomic examination in the first trimester is stressed.
13. Liao AW, Sebire NJ, Geerts L, et al. Megacystis at 10-14 weeks of gestation: chromosomal defects and outcome according to bladder length. Ultrasound Obstet Gynecol 2003; 21:338-341.
14. Goetzl L, Krantz D, Simpson JL, et al. Pregnancy-associated plasma protein A, free β-hCG, nuchal translucency, and risk of pregnancy loss. Obstet Gynecol 2004; 104:30-36. Normal analyte and nuchal translucency results in the first trimester predict lower loss rates at less than 20 weeks of gestation.
15. Krantz D, Goetzl L, Simpson JL, et al. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 2004; 191:1452-1458. Extreme analyte and nuchal translucency results predict high adverse outcome rates.
16. Cheng CC, Bahado-Singh RO, Chen SC, Tsai MS. Pregnancy outcomes with increased nuchal translucency after routine Down syndrome screening. Int J Gynecol Obstet 2004; 84:5-9. Nuchal translucency results greater than or equal to 3 mm predict higher adverse outcome rates, including congenital heart defects.
17. Maymon R, Herman A. The clinical evaluation and pregnancy outcome of euploid fetuses with increased nuchal translucency. Clin Genet 2004; 66:426-436. This paper reviewed studies (1997-2003) involving outcomes for NT greater than or equal to 3 mm in euploid fetuses. Abnormal outcomes occurred in 10-30%.
18. Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER trial). Am J Obstet Gynecol 2004; 191:1446-1451. Adverse outcomes are associated with extreme nuchal translucency and analyte results.
19. Kabili G, Stricker R, Stricker R, et al. First trimester screening for trisomy 21: do the parameters used detect more pathologies than just Down syndrome? Eur J Obstet Gynecol Reprod Biol 2004; 114:35-38. Median MOM for free β-hCG was increased in threatened abortion and PAPP-A median MOM was decreased in women who developed spontaneous abortion or preterm labor.
20. Wald NJ, Simon R, Hackshaw AK. Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies. Prenat Diagn 2003; 23:588-592.
21. Bersinger NA, Noble P, Nicolaides KH. First-trimester maternal serum PAPP-A, SP1 and M-CSF levels in normal and trisomic twin pregnancies. Prenat Diagn 2003; 23:157-162.
22. Maslovitz S, Yaron Y, Fait G, et al. Feasibility of nuchal translucency in triplet pregnancies. J Ultrasound Med 2004; 23:501 -504. Nuchal translucency distribution curves are the same in singletons and triplets.
23. Makrydiamas G, Sociriadis A, Ioannidis JPA. Screening performance of first-trimester nuchal translucency for major cardiac defects: a meta-analysis. Am J Obstet Gynecol 2003; 189:1330-1335.
24. Haak MC, Twisk JWR, Barcelings MM, et al. Ductus venosus flow velocities in relation to the cardiac defects in first-trimester fetuses with enlarged nuchal translucency. Am J Obstet Gynecol 2003; 188:727-733.
25. Favre R, Cherif Y, Kohler M, et al. The role of fetal nuchal translucency and ductus venosus Doppler at 11-14 weeks of gestation in the detection of major congenital heart defects. Ultrasound Obstet Gynecol 2003; 21:239-243.
26. Borrell A. The ductus venosus in early pregnancy and congenital anomalies. Prenat Diagn 2004; 24:688-692. Abnormal ductus venosus flow is associated with aneuploid and euploid fetuses with cardiac malformations or adverse outcome.
27. Galindo A, Comas C, Martinez JM, et al. Cardiac defects in chromosomally normal fetuses with increased nuchal translucency at 10-14 weeks of gestation. J Mat-Fet Neonat Med 2003; 13:163-170. Euploid fetuses with increased nuchal translucency measurements have a significantly increased risk of cardiac defects.
28. Allan LD. Cardiac anatomy screening: what is the best time for screening in pregnancy? Curr Opin Obstet Gynecol 2003; 15:143-146.
29. Chen M, Lam YH, Lee CP, Tang MHY. Ultrasound screening of fetal structural abnormalities at 12 to 14 weeks in Hong Kong. Prenat Diagn 2004; 24:92-97.
30. Sepulveda W, Dezerega V, Be C. First-trimester sonographic diagnosis of holoprosencephaly value of the 'butterfly' sign. Ultrasound Med 2004; 23:761-765. Cross-sectional view of the brain should provide visualization of both choroid plexi at 11-14 weeks.
31. Strenge S, Froster UG, Wanders RJ, et al. First-trimester increased nuchal translucency as a prenatal sign of Zellweger syndrome. Prenat Diagn 2004; 24:150-153.
32. Ferreira A, Matias A, Brandão O, Montenegro N. Nuchal translucency and ductus blood flow as early sonographic markers of thanatophoric dysplasia: a case report. Fetal Diagn Ther 2004; 19:235-241.
33. Kauffmann E, Roman H, Barau G, et al. Case report: a prenatal case of Jarcho-Levin syndrome diagnosed during the first trimester of pregnancy. Prenat Diagn 2003; 23:163-165.
34. Clementschitsch G, Hasenohri G, Steiner H, Staudach A. Early diagnosis of a fetal skeletal dysplasia associated with increased nuchal translucency with 2D- and 3D-ultrasound. Ultraschall Med 2003; 24:349-352.
35. Yaron Y, Ochshorn Y, Tsabari S, Shira AB. First-trimester nuchal translucency and maternal serum free B-hCG and PAPP-A can detect triploidy and determine the parental origin. Prenat Diagn 2004; 24:445-450. Diandric triploidy is associated with very high free β-hCG and elevated nuchal translucency, whereas digynic is associated with very low PAPP-A and free β-hCG.
36. Arbuzova S, Nikolenko M, Krantz D, et al. Low first-trimester pregnancy-associated plasma protein-A and Cornelia de Lange syndrome. Prenat Diagn 2003; 23:861-868.
37. Aitken DA, Irelland M, Berry E, et al. Second-trimester pregnancy associated plasma protein-A levels are reduced in Cornelia de Lange syndrome pregnancies. Prenat Diagn 1999; 15:1035-1040.
38. Westeraard JG, Chemnitz J, Teisner B, et al. Pregnancy-associated plasma protein A: a possible marker in the classification and prenatal diagnosis of Cornelia de Lange syndrome. Prenat Diagn 1983; 3:225-232.
39. Wright D, Bradbury I, Benn P, et al. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 2004; 24:762-766. Contingency screening allows for detection and screen-positive rates similar to the integrated approach but with results available in the first-trimester for most women.
40. Wald NJ, Rodeck C, Hachshaw AK, Rudnicka A. SURUSS in perspective. BJOG 2004; 111:521-531. Various combinations of testing from the SURUSS study are evaluated for screen-positive results based on an 85% detection rate.
41. Rode L, Wøjdemann KR, Shaltni A-C, et al. Combined first- and second-trimester screening for Down syndrome: an evaluation of proMBP as a marker. Prenat Diagn 2003; 23:593-598.
42. Christiansen M, Larsen SO, Oxvig C, et al. Screening for Down's syndrome in early and late first and second trimester using six maternal serum markers. Clin Genet 2004; 65:11-16. Combinations of serum markers with or without nuchal translucency measurements are assessed in three gestational windows (7-9 weeks, 10-12 weeks, and 15-19 weeks).
43. Platt LD, Greene N, Johnson A, et al. Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol 2004; 104:661-666. Independent sequential screening results in high detection of trisomy 21 with a high screen-positive rate.
44. Coco C, Jeanty P, Jeanty C. An isolated echogenic hearts focus is not an indication for amniocentesis in 12,672 unselected patients. J Ultrasound Med 2004; 23:489-496. A detailed anatomic survey and consideration of the a priori risk are important for risk assessment in an unselected population.
45. Filly RA, Benacerraf BR, Nyberg DA, Hobbins JC. Choroid plexus cyst and echogenic intracardiac focus in women at low risk for chromosomal anomalies [editorial]. J Ultrasound Med 2004; 23:447-449. This editorial stated that there was not a need to inform women of findings if risk for aneuploidy is judged to be low.
46. Doubillet PM, Copel JA, Bensen CB, et al. Choroid plexus cyst and echogenic intracardiac focus in women at low risk for chromosomal anomalies: the obligation to inform the mother. J Ultrasound Med 2004; 23:883-885. Response to editorial [45•] above suggesting the need to report 'soft' findings that have been documented to have an association with aneuploidy.
47. Wax JR, Cartin A, Pinette MG, et al. Sonographic grading of fetal intracardiac echogenic foci in a population at low risk of aneuploidy. J Clin Ultrasound 2003; 31:31-38.
48. Porto M, Murata Y, Warneke LA, Keegan KA. Fetal choroid plexus cysts: an independent risk factor for chromosomal anomalies. J Clin Ultrasound 1993; 21:103-108.
49. Bahado-Singh RO, Choi S-J, Oz U, et al. Early second-trimester individualized estimation of trisomy 18 risk by ultrasound. Obstet Gynecol 2003; 101:463-468.
50. Prefumo F, Presti F, Thilaganathan B, Carvalho JS. Association between increased nuchal translucency and second trimester cardiac echogenic foci. Obstet Gynecol 2003; 101:899-904.
51. Wax JR, Cartin A, Pinette MG, Blackstone J. Are intracardiac echogenic foci markers of congenital heart disease in the fetus with chromosome abnormalities? J Ultrasound Med 2004; 23:895-898. Cardiac echogenic foci are not associated with CHD in aneuploid fetuses.
52. Odibo AO, Sehdev HM, Dunn L, et al. The association between nasal bone hypoplasia and aneuploidy. Obstet Gynecol 2004; 104:1229-1233. Nasal bone hypoplasia is associated with an increased risk of aneuploidy.
53. Bromley B, Lieberman E, Shipp TD, Benacerraf B. Fetal nasal bone length: a marker for Down syndrome in the second trimester. J Ultrasound Med 2002; 21:1387-1394.
54. Sonek JD, McKenna D, Webb D, et al. Nasal bone length throughout gestation: normal ranges based on 3537 fetal ultrasound measurements. Ultrasound Obstet Gynecol 2003; 21:152-155.
55. Odibo AO, Raab E, Elovitz M, et al. Evaluating the thresholds of renal pelvic diameter associated with normal postnatal renal function. J Ultrasound Med 2004; 23:513-517. Follow-up of mild pyelectasis with an anteroposterior renal pelvic diameter of less than 7 mm predicts normal postnatal renal function.
56. Signorelli M, Tiberti A, Valseriati D, et al. Width of the fetal lateral ventricular atrium between 10 and 12 mm: a simple variation of the norm? Ultrasound Obstet Gynecol 2004; 23:14-18. Follow-up of 38 children born up to 1997 and 22 from 1998 onward showed normal development after isolated mild ventriculomegaly (10-12 mm) was found on prenatal ultrasound.
57. McEwing RL, Chaqui R. Congenitally corrected transposition of the great arteries: clues for prenatal diagnosis. Ultrasound Obstet Gynecol 2004; 23:68-72.
58. Goncalves LF, Espinoza J, Romero R, et al. A systematic approach to perinatal diagnosis of transposition of the great arteries using 4-dimensional ultrasonography with spatiotemporal image correlation. J Ultrasound Med 2004; 23:1225-1231.
59. Levine D, Barnes PD, Robertson RR, et al. Fast MR imaging of fetal central nervous system abnormalities. Radiology 2003; 229:51-61. Magnetic resonance may demonstrate additional findings that can alter diagnosis.
60. Valsky DV, Ben-Sira L, Porat S, et al. The role of magnetic resonance imaging in the evaluation of isolated mild ventriculomegaly. J Ultrasound Med 2004; 23:519-523.
61. Abe S, Takagi K, Yamamoto T, et al. Semiquantitative assessment of myelination using magnetic resonance imaging in normal fetal brains. Prenat Diagn 2004; 24:352-357.
62. Malinger G, Ben-Sira L, Lev D, et al. Fetal brain imaging: a comparison between magnetic resonance imaging and dedicated neurosonography. Ultrasound Obstet Gynecol 2004; 23:333-340. Magnetic resonance may not add much to a scan performed by a dedicated neurosonographer.
63. Levine D, Barnewolt CE, Mehta TS, et al. Fetal thoracic abnormalities: MR imaging. Radiology 2003; 228:379-388.
64. Frates MC, Kumar AJ, Benson CB, et al. Fetal anomalies: comparison of MR imaging and US for diagnosis. Radiology 2004; 232:398-404.
65. Osada H, Kaku K, Masuda K, et al. Quantitative and qualitative evaluations of fetal lung with MR imaging. Radiology 2004; 231:887-892. MRI may be helpful in predicting fetal pulmonary hypoplasia.
66. Bronsteen R, Lee W, Vettraino IM, et al. Second-trimester sonography and trisomy 18. J Ultrasound Med 2004; 23:233-240.
67. Bronsteen R, Lee W, Vettraino IM, et al. Second-trimester sonography and trisomy 18: the significance of isolated choroid plexus cysts after an examination that includes the fetal hands. J Ultrasound Med 2004; 23:241-245. Examination of fetal hands is important for risk assessment for trisomy 18 when choroid plexus cysts are present.
68. Kuwata T, Matsubara S, Izumi A, et al. Umbilical cord pseudocyst in a fetus with trisomy 18. Fetal Diagn Ther 2003; 18:8-11.
69. Sepulveda W, Corral E, Kottmanns C, et al. Umbilical artery aneurysm: prenatal identification in three fetuses with trisomy 18. Ultrasound Obstet Gynecol 2003; 21:292-296.
70. Heling K-S, Tennstedt C, Chaoui R. Unusual case of a fetus with congenital cystic adenomatoid malformation of the lung associated with trisomy 13. Prenat Diagn 2003; 23:315-318.
71. Bronshtein M, Zimmer EZ, Blazer S. A characteristic cluster of fetal sonographic markers that are predictive of fetal Turner syndrome in early pregnancy. Am J Obstet Gynecol 2003; 188:1016-1020.
72. Coulomb A, Hermine L, Aboura A, et al. Fetal phenotype of Prader-Willi syndrome due to maternal disomy for chromosome 15. Prenat Diagn 2003; 23:938-943.
73. Mammen L, Benson CB. Outcome of fetuses with clubfeet diagnosed by prenatal sonography. J Ultrasound Med 2004; 23:497-500. Fetuses with clubfoot, either unilateral or bilateral, often have other anomalies, aneuploidy, or both.
74. Carbillon L, Uzan M, Largilliere C, et al. Prospective evaluation of uterine artery flow velocity waveforms at 12-14 and 22-24 weeks of gestation in relation to pregnancy outcome and birth weight. Fetal Diagn Ther 2004; 19:381-384. Notching of the uterine artery flow velocity waveform in the first trimester was about threefold that observed in second trimester.
75. Prefumo F, Sebire NJ, Thilaganathan B. Decreased endovascular trophoblast invasion in first trimester pregnancies with high-resistance uterine artery Doppler indices. Human Reprod 2004; 19:206-209. High-resistance uterine artery Doppler indices correlated with decreased trophoblast invasion of decidual vessels.
76. Axt-Fliedner R, Schwarze A, Nelles I, et al. The value of uterine artery Doppler ultrasound in the prediction of severe complications in a risk population. Arch Gynecol Obstet 2005; 271:53-58. In a high-risk population, notches of the uterine artery waveform in the second trimester are a fairly sensitive marker for pregnancy outcome in a high-risk population, while the absence of notches is a very reassuring negative predictor.
77. Harrington K, Fayyad A, Thakur V, et al. The value of uterine artery Doppler in the prediction of uteroplacental complications in multiparous women. Ultrasound Obstet Gynecol 2004; 23:50-55. Doppler uterine artery velocimetry in the second trimester has limited value as a screening tool for low-risk gravidas.
78. Schwarze A, Nelles I, Krapp M, et al. Doppler ultrasound of the uterine artery in the prediction of severe complications during low-risk pregnancies. Arch Gynecol Obstet 2005; 271:46-52. Doppler uterine artery velocimetry in the second trimester has limited value as a screening tool for low-risk gravidas.
79. Gembruch U, Meise C, Germer U, et al. Venous Doppler ultrasound in 146 fetuses with congenital heart disease. Ultrasound Obstet Gynecol 2003; 22:345-350. Doppler velocimetry of the venous circulation was found not to be reliable in screening for fetal cardiac malformations in the second and third trimesters.
80. Gilbert RD. Fetal myocardial responses to long-term hypoxia. Comp Biochem Physiol 1998; 119:669-674.
81. Reed KL, Appleton CP, Anderson CF, et al. Doppler studies of vena cava flows in human fetuses: insights into normal and abnormal cardiac physiology. Circulation 1990; 81:498-505.
82. Axt-Fliedner R, Wiegank U, Fetsch C, et al. Reference values of fetal ductus venosus, inferior vena cava and hepatic vein blood flow velocities and waveform indices during the second and third trimester of pregnancy. Arch Gynecol Obstet 2004; 270:46-55. The normal ranges of blood flow velocities and waveform indices are given for precordial veins in the second and third trimester of pregnancy.
83. Hecher K, Snijders R, Campbell S, et al. Fetal venous, intracardiac, and arterial blood flow measurements in intrauterine growth retardation: relationship with fetal blood gases. Am J Obstet Gynecol 1995; 173:10-15.
84. Ozcan T, Sbracia M, d'Ancona RL, et al. Arterial and venous Doppler velocimetry in the severely growth-restricted fetus and associations with adverse perinatal outcome. Ultrasound Obstet Gynecol 1998; 12:39-44.
85. Baschat AA. Doppler application in the delivery timing of the preterm growth-restricted fetus: another step in the right direction. Ultrasound Obstet Gynecol 2004; 23:111-118. A review of Doppler use in the assessment of fetuses with growth restriction. Precordial venous velocimetry abnormalities, which occur prior to pathological changes in short-term heart rate variability, may be useful in timing delivery for growth-restricted fetuses.
86. Baschat AA, Guclu S, Kush ML, et al. Venous Doppler in the prediction of acid-base status of growth-restricted fetuses with elevated placental blood flow resistance. Am J Obstet Gynecol 2004; 191:277-284. Abnormal ductus venosus velocimetry together with umbilical venous pulsations was the most efficient venous predictor of low umbilical artery pH in growth-restricted fetuses at cesarean delivery.
87. Cheema R, Dubiel M, Breborowicz G, et al. Fetal cerebral venous Doppler velocimetry in normal and high-risk pregnancy. Ultrasound Obstet Gynecol 2004; 24:147-153.
88. Hecher K, Campbell S, Snijders R, et al. Reference ranges for fetal venous and atrioventricular blood flow parameters. Ultrasound Obstet Gynecol 1994; 4:381-390.
89. Bellotti M, Pennati G, De Gasperi C, et al. Simultaneous measurements of umbilical venous, fetal hepatic, and ductus venous blood flow in growth-restricted human fetuses. Am J Obstet Gynecol 2004; 190:1347-1358. In deprivation-based fetal growth restriction, blood flow increases in the ductus venosus at the expense of umbilical venous flow to the liver.
90. Paulick RP, Meyers RL, Rudolph CD, Rudolph AM. Venous responses to hypoxemia in the fetal lamb. J Dev Physiol 1990; 14:81-88.
91. Baschat AA, Gembruch U, Harmon CR. The sequence of changes in Doppler and biophysical parameters as severe fetal growth restriction worsens. Ultrasound Obstet Gynecol 2001; 18:571-577.
92. Hecher K, Bilardo CM, Stigter RH, et al. Monitoring of fetuses with intrauterine growth restriction: a longitudinal study. Ultrasound Obstet Gynecol 2001; 18:564-570.
93. Figueras F, Puerto B, Martinez JM, et al. Cardiac function monitoring of fetuses with growth restriction. Euro J Obstet Gynecol Reproduct Biol 2003; 110:159-163.
94. Bilardo CM, Wolf H, Stigter RH, et al. Relationship between monitoring parameters and perinatal outcome in severe, early intrauterine growth restriction. Ultrasound Obstet Gynecol 2004; 23:119-125. In growth-restricted fetuses, Doppler velocimetry of the ductus venosus is a better predictor of perinatal outcome within 2-7 days of delivery than short-term fetal heart rate variability. It provides a basis for further studies to determine whether Doppler velocimetry can optimize timing of delivery of these fetuses.
95. Ritter S, Jorn H, Weiss C, et al. Importance of ductus venosus Doppler assessment for fetal outcome in cases of intrauterine growth restriction. Fetal Diagn Ther 2004; 19:348-355. A high pulsatility index (without absent or reversed flow) of the ductus venosus did not correlate with perinatal outcome in growth-restricted fetuses less than 32 weeks of gestation.
96. Thornton JG, Hornbuckle J, Vail A, et al. Infant wellbeing at two years of age in Growth Restriction Intervention Trial (GRIT): multicentred randomized controlled trial. Lancet 2004; 364:513-520.
97. Kahler C, Schleussner E, Moller A, et al. Doppler measurements in fetoplacental vessels after maternal betametasone administration. Fetal Diagn Ther 2004; 19:52-57. Maternal glucocorticoid administration to mature fetal lungs did not alter the pulsatility index of the ductus venosus in normal fetuses.
98. Wijnberger LD, Bilardo CM, Hecher K, et al. Effect of antenatal glucocorticoid therapy on arterial and venous blood flow velocity waveforms in severely growth-restricted fetuses. Ultrasound Obstet Gynecol 2004; 23:584-589. Maternal glucocorticoid administration to mature fetal lungs did not alter the pulsatility index of the ductus venosus in growth-restricted fetuses.
99. Wallace EM, Baker LS. Effect of antenatal betamethasone administration on placental vascular resistance. Lancet 1999; 353:1404-1407.
100. Simchen MJ, Alkazaleh F, Adamson SL, et al. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction. Am J Obstet Gynecol 2004; 190:296-304. Maternal injection of β-methasone transiently reduced vascular resistance in the umbilical circulation in about 50% of fetuses with absent or reversed end-diastolic flow in the umbilical artery. The other 50% that maintained absent/reversed diastolic flow after corticosteroid administration had high perinatal morbidity and mortality rates, which supports close monitoring of these fetuses.
101. Sepulveda W, Vanderheyden T, Rather J, et al. Vein of Galen malformation: prenatal evaluation with three-dimensional power Doppler angiography. J Ultrasound Med 2003; 22:1395-1398.
102. Hedrick H, Flake AW, Crombleholme, et al. Sacroccygeal teratoma: prenatal assessment, fetal intervention, and outcome. J Pediatr Surg 2004; 39:430-438.
103. Olutoye OO, Johnson MP, Coleman BG, et al. Abnormal umbilical cord Doppler sonograms may predict impending demise in fetuses with sacrococcygeal teratoma: a report of two cases. Fetal Diagn Ther 2004; 19: 35-39.
104. Shih JC, Ko TL, Lin MC, et al. Quantitative three-dimensional power Doppler ultrasound predicts the outcome of placental chorioangioma. Ultrasound Obstet Gynecol 2004; 24:202-206.
105. Wehrens XH, Offermans JP, Snijders M, et al. Fetal cardiovascular response to large placental chorioangiomas. J Perinat Med 2004; 32:107-112.